Sclerostin inhibitor

This page covers all Sclerostin inhibitor drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting Sclerostin.

Targets

Sclerostin

Phase 3 pipeline (1)

• romosozumab HCP administration with PFS · Amgen · Osteoporosis
  Romosozumab is a monoclonal antibody that targets sclerostin, a protein that inhibits bone formation.